CAMBRIDGE: Acacia Pharma Group announced that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosmo Technologies Limited, a wholly-owned subsidiary of Cosmo Pharmaceuticals N.V. The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS (amisulpride injection) for postoperative nausea & vomiting…